Shares in several pharmaceutical and biotechnology companies have fallen since President-elect Trump announced Thursday that ...

Eli Lilly contends it should be allowed to vet data from 340B hospitals before providing rebates, rather than offer upfront ...

Boston Pharmaceuticals has linked its metabolic dysfunction-associated steatohepatitis (MASH) prospect to improved outcomes ...

Drug manufacturers saw their stock prices fall on Friday after vaccine skeptic Robert F. Kennedy Jr. was announced as Trump's ...

Lilly filed a lawsuit Nov. 14 against HHS head Xavier Becerra and the Health Resources and Services Administration for blocking a plan to change its 340B program from immediate discounts to offering ...

Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

Eli Lilly (LLY) files lawsuit against U.S. health agency over 340B Program rebates, alleging arbitrary blockage of its cash ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.39% and ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on ...

While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant ...